Tesofensine is a triple monoamine reuptake inhibitor — it blocks reuptake of serotonin, dopamine, and norepinephrine simultaneously. Phase 2b clinical trials showed 10-14% body weight loss at 6 months, outperforming most other pharmacological obesity treatments available in 2026. Viking Alternative Medicine offers tesofensine as part of its metabolic optimization program.
What Is Tesofensine?
Tesofensine (NS2330) was originally developed by NeuroSearch as a Parkinson’s and Alzheimer’s treatment. In Phase 2 trials for neurodegeneration, researchers observed significant unintended weight loss in participants — which shifted the drug’s development toward obesity treatment. It is not FDA-approved but is available through physician-supervised protocols in several jurisdictions.
Mechanism of Action
Tesofensine inhibits reuptake transporters for all three major catecholamines:
- Serotonin (5-HT): Appetite suppression, satiety signaling
- Dopamine: Reward pathway modulation — reduces food reward salience
- Norepinephrine: Thermogenesis, energy expenditure increase
This triple action is what makes tesofensine uniquely effective. Single-pathway drugs (SSRIs, SNRIs, pure NRIs) affect appetite minimally. Triple reuptake inhibition produces synergistic effects on both intake reduction and energy expenditure.
Clinical Trial Data
Phase 2b Trial (Sjödin et al., 2008 — Lancet)
Design: 203 obese adults, randomized to placebo, 0.25mg, 0.5mg, or 1.0mg tesofensine daily × 24 weeks
Results (0.5mg dose):
- Mean weight loss: 10.6 kg (vs 2.2 kg placebo) — 8.4 kg net treatment effect
- BMI reduction: 3.9 units
- Waist circumference: −8.5 cm
- Responder rate (≥10% loss): 53% at 0.5mg vs 10% placebo
1.0mg dose: 14.4% weight loss but significantly higher cardiovascular side effects (heart rate +7.4 bpm, BP increase). 0.5mg is the clinical sweet spot — maximum efficacy, acceptable safety profile.
Comparison to Other Agents
| Drug | Mechanism | 6-Month Weight Loss | Status |
|---|---|---|---|
| Tesofensine 0.5mg | Triple monoamine reuptake inhibitor | ~10.6 kg (10.6%) | Not FDA-approved |
| Semaglutide (Ozempic/Wegovy) | GLP-1 receptor agonist | ~10-12% at 68 weeks | FDA-approved |
| Tirzepatide (Zepbound) | GLP-1/GIP dual agonist | ~15-20% at 72 weeks | FDA-approved |
| Phentermine/topiramate | Sympathomimetic + GABA modulator | ~7-9% at 56 weeks | FDA-approved |
| Bupropion/naltrexone | DNRI + opioid antagonist | ~4-5% at 56 weeks | FDA-approved |
Tesofensine and TRT: Why Men 40+ Respond Better
Men with low testosterone carry disproportionate visceral fat — the metabolically active abdominal fat that drives insulin resistance, inflammation, and cardiovascular risk. TRT reduces visceral fat directly; tesofensine compounds this effect by simultaneously suppressing appetite and increasing thermogenesis. Viking patients on combined TRT + tesofensine protocols consistently report superior body composition results vs either therapy alone.
Additionally, dopamine pathway effects of tesofensine can complement testosterone’s mood and motivation improvements — particularly in men with symptoms of anhedonia or low drive.
Dosing Protocol at Viking
Viking physicians prescribe tesofensine in a titrated protocol:
- Weeks 1-4: 0.25mg once daily (morning, with or without food)
- Weeks 5+: 0.5mg once daily if 0.25mg tolerated well
- Maximum dose: 0.5mg/day (1.0mg not used due to cardiovascular risk)
- Cycle length: 3-6 months, reassessed based on results and tolerance
Side Effects and Contraindications
Common (dose-dependent):
- Dry mouth (most common, ~50% at 0.5mg)
- Nausea (typically resolves weeks 2-3)
- Insomnia (take morning dose only)
- Mild heart rate increase (~2-3 bpm at 0.5mg)
- Constipation
Contraindications:
- MAO inhibitors (within 14 days)
- Uncontrolled hypertension (>160/100)
- History of serious cardiovascular events
- Current SSRI/SNRI use (serotonin syndrome risk)
- Active psychosis or bipolar I disorder
Is Tesofensine Available at Viking?
Yes. Viking Alternative Medicine offers tesofensine through its metabolic optimization program in almost every state. Access requires a physician consultation and baseline labs. Because tesofensine is not FDA-approved, it is prescribed under physician discretion as an off-label/investigational agent — similar to other compounds in Viking’s peptide and metabolic optimization portfolio.
Schedule a consultation at vikingalternative.com. Mention metabolic optimization or weight loss as your primary goal during the intake form.
Recent Comments